Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer

NCT02605265 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT02605265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02605265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2015
Completion date
June 30, 2023
Enrollment
356 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer